It depends enormously on dose. At the high, continuous doses used for decades to prevent transplant rejection, rapamycin (sirolimus) causes well-documented issues: mouth ulcers, elevated blood lipids, delayed wound healing, and — mechanistically — insulin resistance from chronic mTORC2 suppression. At the much lower, often intermittent doses tested in recent aging trials, the picture looks different: the Atlas's own human studies report the drug as well tolerated, with only minor adverse events.
The mechanism behind the metabolic side effects
SAR2006D — chronic rapamycin dosing eventually suppresses mTORC2 signaling too, not just mTORC1 — and mTORC2 is what phosphorylates Akt/PKB, a key node in insulin signaling. This is the mechanistic basis for rapamycin-associated insulin resistance: it's a chronic-dosing, off-target effect, not what the drug was designed to do.
What the Atlas's low-dose human trials actually report
KRA2018B — a safety-first pilot RCT (n=25, ages 70–95) asking the basic tolerability question before any longevity trial: daily rapamycin over 8+ weeks was well tolerated, with only minor adverse events.
MAN2018B — a low-dose, selective mTORC1-inhibiting combination in 264 elderly people improved immune function — the opposite direction of "more immunosuppression", showing dose and selectivity change the safety picture, not just the benefit.
GIL2026B — low-dose rapamycin in ME/CFS patients reduced fatigue symptoms and modulated inflammation without the profile reported at transplant-immunosuppression doses.
MOE2025B — a 48-week RCT (n=114) at an aging-relevant dose found no significant change in its primary endpoint — a null efficacy result, but also no signal of the adverse effects associated with chronic high-dose use.
Not every rapalog trial succeeds — or is side-effect free
MAN2021B — the crucial reality check: after a promising phase 2a, the large phase 3 trial (n=1024) of RTB101 (a rapalog-class mTOR inhibitor) FAILED its primary endpoint for reducing respiratory illness — a reminder that dose-sparing strategies don't automatically preserve efficacy just because they reduce side effects.
Why the dose distinction matters
Nearly everything people cite as "rapamycin's side effects" — mouth sores, hyperlipidemia, poor wound healing — comes from the transplant-immunosuppression literature, where the drug is dosed continuously and at levels that fully occupy mTORC1 (and, over time, mTORC2). The aging-research community's central bet is that much lower, often intermittent dosing keeps enough benefit while avoiding that profile — a bet the Atlas's open question on mTORC1-selective, mTORC2-sparing dosing and pulsed dosing track directly.
